Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: A case report

MedGenMed Medscape General Medicine

Volumn 10, Issue 11, 2008, Pages

  Rifkin, Stephen I ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CARVEDILOL; CLONIDINE; CLOPIDOGREL; CREATINE KINASE; CREATININE; CYCLOSPORIN; DILTIAZEM; ESOMEPRAZOLE; FLUDROCORTISONE; FUROSEMIDE; INSULIN GLARGINE; METOPROLOL; MYOGLOBIN; RANOLAZINE; SERTRALINE; SIMVASTATIN; TAMSULOSIN; ACETANILIDE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAZOLE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIPERAZINE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BELOW KNEE AMPUTATION; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; GRAFT RECIPIENT; HEART FAILURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MALE; MYALGIA; RHABDOMYOLYSIS; TREATMENT DURATION; WEAKNESS; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; MIDDLE AGED;

ACETANILIDES; ADRENERGIC ALPHA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; CARBAZOLES; DILTIAZEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PIPERAZINES; PROPANOLAMINES; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 57049137177     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(suppl):69C-76C.
2. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-2590.
3. Ballantyne, CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
4. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol. 2006;97(suppl):89C-94C.
5. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Therapeutics. 2007;29:1761-1770.
6. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16:352-358.
7. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-295.
8. Jerling M, Huan B-L, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45:422-433.
9. Gladding P, Pilmore H, Edwards C, Potentially fatal interaction between diltiazem and statins. Ann Intern Med. 2004;140:W-31.